Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Moderna and Merck have released top-line results saying their mRNA cancer vaccine cut death and recurrence by 42%. The companies had previously reported that the trial succeeded.
AI summary · generated only from source feed metadata; consult originalSource published
Published here
views4
Original source
Ars Technica
Media report · consult original reporting
Read the original ↗https://arstechnica.com/health/2026/10/personalized-mrna-cancer-vaccine-cut-melanoma-death-recurrence-by-42/Original headline
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
AI bilingual edit · consult originalHeadlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.